HER2 binders

Patent metadata

Field	Value
Publication number	US-10894097-B2
Application number	US-201816145115-A
Country	US
Kind code	B2
Filing date	Sep 27, 2018
Priority date	Dec 22, 2008
Publication date	Jan 19, 2021
Grant date	Jan 19, 2021

Abstract

Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

First claim

The invention claimed is:

1. A method of imaging at least a portion of a subject comprising:
administering a composition to the subject, wherein the composition comprises an isolated polypeptide and an 18 F coupled to the peptide through a bifunctional linker molecule, wherein the 18 F is coupled to the bifunctional linker via an aminoxy group,
wherein the isolated polypeptide comprises SEQ. ID No. 1 or SEQ. ID No. 2, and
wherein the isolated polypeptide binds specifically to HER2; and

imaging the subject with PET.

2. The method of claim 1 , further comprising the step of diagnosing the subject with a HER2 expressing cancer.

3. The method of claim 2 , wherein the HER2 expressing cancer is breast cancer.

4. The method of claim 1 , wherein the bifunctional aminoxy linker is a tert-butyl 2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethylamino)-2-oxoethoxycarbamate linker.

5. The method of claim 1 , wherein the ′ 8 F is conjugated to the isolated polypeptide via the bifunctional aminoxy linker at the N-terminus of the isolated polypeptide.

6. The method of claim 1 , further comprising the step of monitoring delivery of the composition to the subject.

7. A method of imaging at least a portion of a subject comprising:
administering a composition to the subject, wherein the composition comprises an isolated polypeptide comprising SEQ. ID No. 2 conjugated with a 18 F via a tert-butyl 2-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethylamino)-2-oxoethoxycarbamate linker, wherein the isolated polypeptide binds specifically to HER2; and
imaging the subject with PET.

8. The method of claim 7 , further comprising the step of diagnosing the subject with a HER2 expressing cancer.

9. The method of claim 8 , wherein the HER2 expressing cancer is breast cancer.

10. The method of claim 7 , further comprising the step of monitoring delivery of the composition to the subject.

Assignees

• Gen Electric
• Affibody Ab

Inventors

• Syud Faisal Ahmed
• Lee Brian Duh-Lan
• Zhang Rong
• Iveson Peter Brian
• Schaffer Paul
• Simonsson Tove
• Gunneriusson Elin
• Frejd Fredrik
• Abrahmsen Lars
• Feldwisch Joachim
• Herne Nina
• Lendel Christofer

Classifications

• C07K14/71

  for growth factors; for growth regulators · CPC title

• A61K51/088 Primary

  conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title